Herbal Remedies: Adverse Effects and Drug Interactions
Am Fam Physician. 1999 Mar 1;59(5):1239-1244.
See related patient information handout on herbal health products, written by the author of this article.
A growing number of Americans are using herbal products for preventive and therapeutic purposes. The manufacturers of these products are not required to submit proof of safety and efficacy to the U.S. Food and Drug Administration before marketing. For this reason, the adverse effects and drug interactions associated with herbal remedies are largely unknown. Ginkgo biloba extract, advertised as improving cognitive functioning, has been reported to cause spontaneous bleeding, and it may interact with anticoagulants and antiplatelet agents. St. John's wort, promoted as a treatment for depression, may have monoamine oxidase–inhibiting effects or may cause increased levels of serotonin, dopamine and norepinephrine. Although St. John's wort probably does not interact with foods that contain tyramine, it should not be used with prescription antidepressants. Ephedrine-containing herbal products have been associated with adverse cardiovascular events, seizures and even death. Ginseng, widely used for its purported physical and mental effects, is generally well tolerated, but it has been implicated as a cause of decreased response to warfarin. Physicians must be alert for adverse effects and drug interactions associated with herbal remedies, and they should ask all patients about the use of these products.
Increasingly, alternative therapies such as herbal products are being used in the United States. Approximately 25 percent of Americans who consult their physician about a serious health problem are employing unconventional therapy, but only 70 percent of these patients inform their physician of such use.1
Herbal products are not tested with the scientific rigor required of conventional drugs, and they are not subject to the approval process of the U.S. Food and Drug Administration (FDA). Herbal products therefore cannot be marketed for the diagnosis, treatment, cure or prevention of disease. Nonetheless, the Dietary Supplement Health and Education Act of 1994 allows these products to be labeled with statements explaining their purported effect on the structure or function of the human body (e.g., alleviation of fatigue) or their role in promoting general well-being (e.g., enhancement of mood or mentation).2 Analysis of some of the putative effects of herbal products shows that they sometimes closely resemble claims of clinical efficacy for various diseases or conditions.
Unlike conventional drugs, herbal products are not regulated for purity and potency.2 Thus, some of the adverse effects and drug interactions reported for herbal products could be caused by impurities (e.g., allergens, pollen and spores) or batch-to-batch variability. In addition, the potency of an herbal product may increase the possibility of adverse effects.
Because physicians are likely to encounter patients who are using herbal remedies, they need to be aware of the purported effects of these products. They also need to be cognizant of the adverse effects of herbal remedies (Table 1) and the possibility of deleterious drug interactions (Table 2).
Side Effects of Select Herbal Products
|Herbal product||Side effects|
St. John's wort
Gastrointestinal disturbances, allergic reactions, fatigue, dizziness, confusion, dry mouth, photosensitivity
Ephedra (ma huang)
Hypertension, insomnia, arrhythmia, nervousness, tremor, headache, seizure, cerebrovascular event, myocardial infarction, kidney stones
Sedation, oral and lingual dyskinesia, torticollis, oculogyric crisis, exacerbation of Parkinson's disease, painful twisting movements of the trunk, rash
Drug Interactions with Herbal Products
|Herbal product||Interacting drugs|
Aspirin, warfarin (Coumadin), ticlopidine (Ticlid), clopidogrel (Plavix), dipyridamole (Persantine)
St. John' s wort
Caffeine, decongestants, stimulants
Sedatives, sleeping pills, antipsychotics, alcohol
The active ingredients in Ginkgo biloba extract account for its antioxidant properties and its ability to inhibit platelet aggregation.3 Consequently, this herbal product is promoted for use in improving cognitive function and blood flow.4 To date, however, at least four reports of spontaneous bleeding in association with use of Ginkgo biloba have been published.4–8
One report4 described a 70-year-old man who presented with bleeding from the iris into the anterior chamber of the eye one week after beginning a self-prescribed regimen consisting of a Ginkgo biloba concentrated extract (Ginkoba), in a dosage of 40 mg twice daily. His medical history included coronary artery bypass surgery performed three years previously. His only medication was aspirin, in a dosage of 325 mg per day, which he had taken since his bypass surgery. After the spontaneous bleeding episode, he continued to take aspirin but discontinued the ginkgo product. Over a three-month follow-up period, he had no further bleeding episodes. Interaction of the ginkgo product and aspirin was considered the cause of his ocular hemorrhage.
Ginkgo biloba may also interact with warfarin (Coumadin). A 78-year-old woman who had been taking warfarin for five years after coronary bypass surgery suffered a left parietal hemorrhage after using a ginkgo product for two months.5 No change was noted in her prothrombin time. The intracerebral bleeding was attributed to the antiplatelet effects of ginkgo.
In another reported case,6 a 33-year-old woman was diagnosed with bilateral subdural hematomas after almost two years of ingesting Ginkgo biloba, in a dosage of 60 mg twice daily. Her other medications were acetaminophen and an ergotamine-caffeine preparation, which she used briefly. While she was taking Ginkgo biloba, her bleeding times were 15 and 9.5 minutes. Within 35 days after she stopped taking the ginkgo product, her bleeding times were normal (three to nine minutes).
An additional case of spontaneous intracerebral hemorrhage was reported in a 72-year-old woman who had been taking Ginkgo biloba, in a dosage of 50 mg three times daily, for approximately six months.7 No history of head trauma could be elicited.
Until further information is available, patients who are taking garlic, vitamin E,8 warfarin, aspirin or other drugs with antiplatelet or anticoagulant effects should be cautioned about potential interactions with ginkgo products. Patients who are taking ginkgo products should be counseled to inform their physician about unusual bleeding or bruising, new-onset headaches or vision changes.
St. John's Wort
St. John's wort (Hypericum perforatum) is an herb widely promoted as a “natural” antidepressant.9 In Germany, this herb is commonly prescribed for various psychopathologic conditions involving depression and anxiety. Herbal products are permitted to be marketed in Germany if they fit general criteria in published monographs.10 However, the safety and efficacy of St. John's wort are not evaluated in the appropriately designed studies that the FDA requires for antidepressant drugs.
The German monograph10 for St. John's wort identifies hypericin, a purported monoamine oxidase (MAO) inhibitor, as the active ingredient in the herb. The hypericin content of St. John's wort is used as the basis for dosing. However, one U.S. study11 showed that pure hypericin does not bind to MAO. In this study, a crude St. John's wort extract exhibited significant receptor affinity for MAO, but the investigators stated that concentrations of the crude extract required for this activity are unlikely to be achieved after oral administration.
No instances of an interaction between tyramine-containing foods and St. John's wort have been reported, but drug interactions may be of concern. One report12 described a 50-year-old woman who had taken St. John's wort powder, in a dosage of 600 mg per day for 10 days, and then took one 20-mg dose of paroxetine (Paxil). She became incoherent and lethargic and also complained of nausea, weakness and fatigue. Interestingly, the woman had been taking paroxetine, in a dosage of 40 mg per day, for eight months; she discontinued the paroxetine when she started taking St. John's wort.
Studies have shown that St. John's wort extract inhibits serotonin,13 dopamine and norepinephrine reuptake in vitro.14 Consequently, it would be prudent to avoid the concomitant use of St. John's wort and antidepressants until further information is available. Given that the half-life of hypericin is 24 to 48 hours,15 a conservative recommendation would be to wait until two weeks after a patient has stopped taking St. John's wort and then prescribe an antidepressant. However, if a patient needs to be started on an antidepressant expeditiously, a relatively long “washout period” may not be practical.
Despite the paucity of evidence for food and drug interactions with St. John's wort, patients who use this herb and then begin taking antidepressants or other serotonergic drugs should be observed carefully for adverse effects. Side effects of St. John's wort include dry mouth, dizziness and confusion.9 In one open study16 of more than 3,000 patients, gastrointestinal symptoms, allergic reactions and fatigue were reported by 0.6 percent, 0.5 percent, and 0.4 percent of patients, respectively.
Phototoxicity manifested as elevated, itching, erythematous lesions has also been reported in association with the use of St. John's wort.17 Neuropathy associated with sun exposure is another manifestation of phototoxicity. In one case report,18 a 35-year-old woman developed stinging pain on sun-exposed areas after four weeks of self-treatment with ground St. John's wort. Her pain was worsened by cold, minimal mechanical stimuli and sun exposure. After she stopped taking St. John's wort, her symptoms resolved gradually over two months. The patient's symptoms were attributed to demyelination of cutaneous axons caused by photoactivated hypericins.
Ephedrine and related alkaloids are the pharmacologically active moieties of the extract of Ephedra (a genus of shrubs).19 Ephedrine constitutes 30 to 90 percent of the alkaloids of Ephedra species. The extract of some species also contains pseudoephedrine.
Ephedra (ma huang) is commonly found in herbal weight-loss products referred to as “herbal fen-phen.” Some weight loss clinics and retail outlets promote herbal products as an alternative to the use of fenfluramine (Pondimin) and dexfenfluramine (Redux), the prescription anorexiants recently removed from the U.S. market.20 Herbal fen-phen products that also contain St. John's wort are sometimes referred to as “herbal Prozac.”
Ephedrine-containing products are also marketed as decongestants, bronchodilators and stimulants.21 Other promoted uses include enhancement of athletic performance and body-building efforts. Marketed uses of ephedrine-containing products such as “herbal ecstasy” include induction of a euphoric state and heightening of awareness and sexual sensations.22 The FDA has advised consumers not to use ephedrine-containing products marketed as alternatives to street drugs.23
In the past few years, the FDA has investigated more than 800 reports of adverse reactions associated with more than 100 different products that contained or were thought to contain Ephedra alkaloids.21 Reported adverse reactions have included insomnia, nervousness, tremor, headaches, hypertension, seizures, arrhythmias, heart attack, stroke and death. Approximately 56 percent of the reported adverse effects occurred in persons younger than 40 years old; about another 25 percent occurred in persons 40 to 49 years of age. The relatively young age group in which serious cardiovascular events have occurred is of concern.
In response to the reports of cardiovascular effects, the FDA has proposed a dosage limit of 8 mg every six hours (24 mg per day) for ephedra alkaloids. The proposed rule also calls for a label advising consumers not to use an ephedrine-containing product for more than seven days and warning that exceeding the recommended dosage may result in heart attack, stroke, seizure or death. The Association of Food and Drug Officials (AFDO), which represents state food and health department officials, believes that serious adverse effects to ephedrine-containing products may occur even at a dosage of 24 mg per day.24 In fact, life-threatening adverse reactions have been reported to occur with doses of 1 to 5 mg (dosages of 4 to 20 mg per day).25 AFDO is also concerned that setting a dosage limit may imply that a safe dose exists.24
Ephedra-containing products have also been associated with the development of kidney stones. Ephedrine, pseudoephedrine and metabolites comprised almost 100 percent of a radiolucent stone removed from a 27-year-old male body builder who took up to 12 Pro-Lift tablets daily. Each tablet was found to contain approximately 10 mg of ephedrine. Information from a large kidney stone database shows that this is not an isolated incident; over 100 ephedrine-containing kidney stones were identified from January 1996 to June 1997. It is not known how many of these stones were associated with the use of herbal ephedrine-containing products.26
The risks of using ephedrine-containing supplements appear to outweigh the benefits. Consequently, patients should be advised not to use these products if they are sensitive to the effects of sympathomimetic agents.21 Such patients include those with hypertension, hyperthyroidism, diabetes mellitus, psychiatric conditions, glaucoma, prostate enlargement, seizure disorders and cardiovascular disease. Concomitant use of ephedrine-containing products and caffeine or other stimulants should also be discouraged.
Little scientific evidence shows that ginseng is effective for any purpose. Nonetheless, this herb has been purported to strengthen normal body functions, increase resistance to stress and improve sexual function.27 Ginseng is generally well tolerated, but a probable interaction between the herb and warfarin has been reported.28
A 47-year-old man with a mechanical heart valve who was taking warfarin to prevent thromboembolic events experienced a decline in International Normalized Ratio (INR) from 3.1 to 1.5 (target INR: 2.5 to 3.5) two weeks after he began taking a ginseng product (Ginsana) three times daily to improve his “energy level.”28 For the nine months before he started taking the ginseng product, his INR had ranged from 3 to 4. His other medications included diltiazem (Cardizem), nitroglycerin and salsalate (Disalcid); he had been taking all three drugs for at least three years. The patient denied changes in drug therapy or diet, and he stated that he was not taking dietary supplements other than the ginseng product. Two weeks after he discontinued use of the ginseng product, his INR was 3.3. Because of the risks associated with a decreased INR, the patient was not rechallenged with ginseng.
Until studies or additional case reports can verify the interaction between ginseng and warfarin, it would be prudent to closely monitor patients on warfarin who begin taking dietary supplements that contain this herb. A possible mechanism for this interaction is not yet known.
Kava is an herbal sedative with purported antianxiety or calming effects. In one case series involving four patients,29 kava was associated with extrapyramidal effects at dosages of 100 to 450 mg per day. Symptoms occurred 90 minutes after one patient took a single 100-mg dose, four hours after one patient took a single 100-mg dose, four days after one patient began taking 150 mg three times daily, and 10 days after one patient began taking 150 mg twice daily. The extrapyramidal side effects included oral and lingual dyskinesia, torticollis, painful twisting movements of the trunk, oculogyric crisis and exacerbation of Parkinson's disease.
Kava has also been shown to have additive effects with central nervous system depressants. A patient who was taking alprazolam (Xanax), cimetidine (Tagamet) and terazosin (Hytrin) became lethargic and disoriented after ingesting kava.30
Kava should not be used with benzodiazepines, barbiturates, antipsychotics and alcohol. In addition, patients with Parkinson's disease should be discouraged from using kava products.
Kava dermopathy has been reported with the use of kava as a traditional South Pacific beverage. Recently, two cases associated with use of commercially available kava preparations were reported.31 A 70-year-old man who had been taking kava extract for anxiety for two to three weeks experienced itching several hours after sun exposure. Erythematous, infiltrated plaques then developed on his face, chest and back. A similar case involved a 52-year-old woman who presented with papules and plaques on her face, arms, back and chest after taking a kava extract for three weeks. In both cases, biopsy revealed lymphocytic infiltration of the dermis with destruction of the sebaceous glands. Because kava is lipophilic, it was hypothesized that kava can concentrate in sebaceous oils and trigger an immune response, resulting in a drug reaction.31
Because dietary supplements are becoming increasingly popular, physicians need to ask questions about the use of herbal products as part of the medication history (Table 3). Even though herbal products are available without a prescription, medical guidance is necessary because of the adverse effects of these products and the potential for drug interactions. Consequently, physicians need to stay abreast of trends in dietary supplement use, with the realization that for most supplements the adverse effects and potential for drug interactions are not well characterized.
Questions to Ask Patients Who May Be Taking Herbal Products
Are you taking an herbal product, herbal supplement or other “natural remedy?”
If so, are you taking any prescription or nonprescription medications for the same purpose as the herbal product?
Have you used this herbal product before?
Are you allergic to any plant products?
Are you pregnant or breast-feeding?
Objective information about herbal products can be obtained in publications such as Alternative Medicine Alert (800-688-2421) and Review of Natural Products (314-216-2100). Physicians can help broaden knowledge in this area by reporting adverse events to the FDA's MedWatch Program (800-FDA-1088).
1. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246–52.
2. Dietary Supplement Health and Education Act of 1994. Public Law No. 103–417 1994
3. Foster S. Herbal medicine: an introduction for pharmacists. NARD J. 1996;10:127–44.
4. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [Letter]. N Engl J Med. 1997;336:1108.
5. Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage [Letter]. Neurology. 1998;50:1933–4.
6. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. 1996;46:1775–6.
7. Gilbert GJ. Ginkgo biloba [Letter]. Neurology. 1997;48:1137.
8. Gianni LM, Dreitlein WB. Some popular OTC herbals can interact with anticoagulant therapy. US Pharmacist. 1998;23( May):8083–486.
9. St. John's wort. Med Lett Drugs Ther. 1997;39:107–8.
10. Blumenthal M, ed. Complete German Commission E monographs.; therapeutic guide to herbal medicines. Austin, Tex.: American Botanical Council, 1998.
11. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry. 1997;30(suppl 2):108–12.
12. Gordon JB. SSRIs and St. John's wort: possible toxicity [Letter]? Am Fam Physician. 1998;57:950,953.
13. Müller WE, Rolli M, Schafer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 1997;30 (suppl 2):102–7.
14. Perovic S, Müller WE. Pharmacological profile of Hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung. 1995;45:1145–8.
15. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother. 1996;40:2087–93.
16. Woelk H, Burkand G, Grunwald J. Benefits and risks of the Hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol. 1994;7(suppl 1):S34–8.
17. Golsch S, Vocks E, Rakoski J, Brockow K, Ring J. Reversible increase in photosensitivity to UV-B caused by St. John's wort extract [German]. Hautarzt. 1997;48:249–52.
18. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St. John's wort [Letter]. Lancet. 1998;352:1121–2.
19. The ephedras. Lawrence review of natural products. In: Drug facts and comparisons. St. Louis: Facts and Comparisons, 1995.
20. FDA warns against drug promotion of “herbal fenphen.“ In: FDA Talk Paper. Rockville, Md.: Department of Health and Human Services, Food and Drug Administration, Nov. 6, 1997. Retrieved October 1998 from the World Wide Web: http://www.fda.gov/bbs/topics/ANSWERS/ANS00832.html.
21. Dietary supplements containing ephedrine alkaloids; proposed rule. 21 CFR Part 111. Fed Register 1997; 62(107):30677–724. Retrieved October 1998 from the Internet: http://frwebgate2.access.gpo.gov/cgi-bin.
22. Future marketing of ephedrine “street drugs” is “irresponsible,” FDA tells six companies. Tan Sheet 1997;4(36):9. Retrieved October 1998 from the World Wide Web: http://www.dialogweb.com/search/html.
23. Street drug alternatives with ephedra. FDA Consumer. 1996;30(5):4.
24. Ephedrine alkaloids 8 mg per serving limit “too high,” state food, drug officials say. Tan Sheet 1997; 5(50):11–3. Retrieved October 1998 from the World Wide Web: http://www.dialogweb.com/search.html.
25. Serious “adverse” events reported for ephedrine supplements in 1–5 mg range—FDA. Tan Sheet 1997;4(36):4–6. Retrieved October 1998 from the World Wide Wed: http://www.dialogweb.com/search.html.
26. Powell T, Hsu FF, Turk J, Hruska K. Mahuang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis. 1998;32:153–9.
27. Tyler VE. The honest herbal. 3d ed. New York: Pharmaceutical Products Press, 1993.
28. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health/Syst Pharm. 1997;54:692–3.
29. Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine antagonism [Letter]. J Neurol Neurosurg Psychiatry. 1995;58:639–40.
30. Almedia JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam [Letter]. Ann Intern Med. 1996;125:940–1.
31. Jappe U, Franke I, Reinhold D, Gollnick HP. Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J Am Acad Dermatol. 1998;38:104–6.
Richard W. Sloan, M.D., R.PH., coordinator of this series, is chairman and residency program director of the Department of Family Medicine at York (Pa.) Hospital and clinical associate professor in family and community medicine at the Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pa.
Copyright © 1999 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.